Loading
A phase 1 trial of ITR-251 run by ITERIA BIOPHARMA, S.L., not yet recruiting.
ITR-251 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT07870096 by ITERIA BIOPHARMA, S.L., with 46 participants planned, started 2026-10. Conditions recorded: Solid Tumor Cancer and Castration Resistant Metastatic Prostate Cancer. Interventions recorded: ITR-251, ITR-251 at RP2D, ARPI therapy and Androgen Deprivation Therapy (ADT).
Shares Metastatic castration-resistant prostate cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/